Andrew Chadeayne

Andrew Chadeayne

Founder & CEO at CaaMTech
Issaquah, Washington, United States

Seattle-area CaaMTech Raises $22M to Develop Novel Tryptamines, Aiming for Human Testing

Seattle-area startup CaaMTech raised $22 million to develop synthesized tryptamine compounds similar to those in psilocybin and LSD, aiming to create defined formulations that maximize desired psychedelic effects and minimize side effects. The company says many of its novel agents are unscheduled in the U.S., and it plans to advance toward human testing amid growing investment and interest in psychedelics for mental-health treatments.

Organizations

See all 6
  • CaaMTech logo
    CaaMTech Founder & CEO 2019–present · current
  • Ebbu Chief Innovations Officer 2017–2018 · past
  • NewMarket Pharmaceuticals Director of Intellectual Property 2011–2013 · past

Education

  • The George Washington University Law School J.D., Patent Law · 2007–2011
  • Cornell University Doctor of Philosophy - PhD, Chemistry · 2001–2006
  • Princeton University Bachelor of Arts, Neuropsychology and Chemistry · 1997–2001
  • Pleasantville High School

Online